Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

North China Pharmaceutical Hebei Huamin Pharmaceutical Co., Ltd., established on 2010-04-28, The business scope includes powder injection(Cephalosporins),tablet(Contains cephalosporins),Granules(Cephalosporins),hard capsule(Contains cephalosporins),Sterile API,Production of raw materials and semi-synthetic antibiotic intermediates(Except for those prohibited by the state or subject to approval);Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval);Biotechnology product development and technical consulting services;Pharmaceutical Technology Consulting Services;Business Consulting Services;Drug registration agent business;Scenic spot management service;Information technology service;Housing rental service;Maintenance of electrical instruments,Install,Sales service;Pharmaceutical Equipment Manufacturing,repair,Install,Sales service;Confectionery,Pharmaceutical Intermediates(Hazardous chemicals and first-class pharmaceutical precursor drugs,National Prohibition,Except for restricted items)production and sales of;Chemical Products(Hazardous chemicals and first-class pharmaceutical precursor drugs,National Prohibition,Except for restricted items),Packaging Materials,food additives,Feed additives,natural extract,medical supplements,Pre-packaged food,Sales of health food;Exhaust gas treatment;sewage treatment;Operation Management of Sludge Disposal Facility,maintain;Environmental Technology Consulting,technology transfer,Technical Services(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. It offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Suzhou Shengda Pharmaceutical Co., Ltd., established on 1998-11-10, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Drug retail;Drug import and export;Technology Import and Export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Specialty Chemicals Sales(Free of Hazardous Chemicals);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Non-residential real estate leases;market survey(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Yuhan Corp. engages in the manufacture of pharmaceutical, health foods, cosmetics and consumer products. It operates through the following business areas: Pharmaceutical, Household products and Active Pharmaceutical Ingredient (API). Its products include APIs and intermediates and finished products such as ethical drugs, over-the-counter drugs and others. Its services include custom development and manufacturing services and supply chain management. The company was founded by Il-Han New on June 20, 1926 and is headquartered Seoul, South Korea.

Sichuan Pharmaceutical, Inc., a subsidiary of Sichuan Huili Weike Investment Development Group Ltd., is a Chinese company. The firm operates as pharmaceutical company.

Hainan Meida Pharmaceutical Co., Ltd., established on 2008-03-13, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)General project:Biochemical product technology research and development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Non-residential real estate leases;property management(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

Zhejiang Anglikang Pharmaceutical Co., Ltd. engages in the research, development, production and sales of pharmaceutical drugs. Its products include cephalosporins, cardiovascular, nephropathy and gastrointestinal tract drugs. The company was founded on December 30, 2001 and is headquartered in Shenzhou, China.

Disha Pharmaceutical Group Co., Ltd., established on 1997-04-30, Business range includes tablet,Granules,hard capsule(cephalosporins),Production and sales of small-volume injections of the company's products(The validity period is subject to the license);Chinese Herbal Medicine(Contains direct oral tablets,Processing range:Purification,cut,Fried,Broiled,steamed,cook,stew,Forging,charcoal,control)production and sales of(The validity period is subject to the license);Production and sales of health food(The scope and validity period of the license shall be subject to the Food Hygiene License);the first sort,Production and sales of Class II medical devices;the first sort,Class II medical device business;food production;food sales;Production of food additives,Sales;Import and export of goods and technologies within the filing scope;Research and development of marine biological products,Production,Sales,technology development,Technology transfer and technical consulting services;Indoor and outdoor decoration engineering construction;Inspection and testing services for drug structure confirmation;disinfection products(Free of Hazardous Chemicals),Production and sales of labor insurance products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. engages in the manufacture, sale, research and development of pharmaceutical products. Its products include anti-infective, antiviral, respiratory system, digestive system, nervous, endocrine, cardiovascular system, antipyretic, analgesics & anti-inflammatory, oncology, anti-allergic APIs & intermediates, lyophilized powder for injection preparation, solid preparation, chemical raw medicine, cephalosporin raw medicine and oral cephalosporin series. The company was founded on December 14, 1995 and is headquartered in Linyi, China.

Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd., part of Sino Biopharmaceutical Ltd., is a company headquartered in Huaian, China. The firm produces pharmaceutical products.

Established in 1987, Korea United Pharm. Inc. has continued to develop as a pharmaceutical company with its slogan of "Korean owned multinational pharmaceutical company." We have continuously launched new pharmaceutical drugs such as Cilostan CR Tab, Gastiin CR Tab, Clanza CR Tab and etc., through prestigious R&D investment, abundant know-hows and top expert researchers and have been placed as a strong competitor in the pharmaceutical drug development industry. they were named one of Asia's 200 most promising companies by the US economy magazine Forbes.

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.

Part of Shandong Jincheng Pharmaceutical Group Co., Ltd., Shanghai Jincheng Pharmaceutical Co. Ltd. is a company headquartered in Shanghai, China. The firm manufactures pharmaceutical products. On June 26, 2014 Shandong Jincheng Pharmaceutical Group Co., Ltd. acquired Shanghai Jincheng Pharmaceutical Co. Ltd. for $8.07 million.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

Koninklijke DSM NV engages in the manufacture and sale of nutritional and pharmaceutical ingredients, and industrial chemicals. It operates through the following segments: Nutrition, Materials, Innovation Center, and Corporate Activities. The Nutrition segment serves the global industries for animal feed, food and beverage, pharmaceuticals, infant nutrition, dietary supplements, and personal care. The Materials segment deals with specialty plastics, which are used in components for the electrical and electronics, automotive, flexible food-packaging, and consumer goods industries. The Innovation Center segment focuses on innovation and the growth of DSM's existing core business through adjacent technologies. The Corporate Activities segment consists of operating and service activities as well as other several costs. The company was founded in 1902 and is headquartered in Herleen, the Netherlands.